Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01824290
Other study ID # 10609
Secondary ID H6D-MC-LVHV2012-
Status Completed
Phase Phase 3
First received
Last updated
Start date February 5, 2014
Est. completion date March 10, 2021

Study information

Verified date November 2021
Source Eli Lilly and Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension. Participants will receive study treatment for 6 months in the double-blind period (Period 1), and then will be eligible to enroll into an open-label 2 year extension period (Period 2) during which participants will receive tadalafil.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date March 10, 2021
Est. primary completion date March 18, 2019
Accepts healthy volunteers No
Gender All
Age group 6 Months to 17 Years
Eligibility Inclusion Criteria: - =6 months to <18 years of age at screening - Currently have a diagnosis of PAH that is either: - idiopathic, including hereditary - related to connective tissue disease - related to anorexigen use - associated with surgical repair of at least 6-month duration of congenital systemic to pulmonary shunt (eg, atrial septal defect, ventricular septal defect, patent ductus arteriosus) - Have a history of a diagnosis of PAH established by a resting mean pulmonary artery pressure (mPAP) =25 millimeter of mercury (mm Hg), pulmonary artery wedge pressure =15 mm Hg, and a pulmonary vascular resistance (PVR) =3 Wood units via right heart catheterization (RHC). In the event that a pulmonary artery wedge pressure cannot be obtained during RHC, participants with a left ventricular end diastolic pressure (LVEDP) <15 mm Hg, with normal left heart function, and absence of mitral stenosis on echocardiography can be eligible for enrollment - Have a World Health Organization (WHO) functional class value of II or III at the time of screening - All participants must be receiving an endothelin receptor antagonist (ERA) (such as bosentan or ambrisentan) and must be on a maintenance dose with no change in dose (other than weight-based adjustments) for at least 12 weeks prior to screening and have a screening aspartate transaminase (AST)/alanine transaminase (ALT) <3 times the upper limit of normal (ULN) - If on conventional PAH medication, including but not restricted to, anticoagulants, diuretics, digoxin, and oxygen therapy, the participant must be on stable doses with no changes (other than weight-based adjustments) for at least 4 weeks before screening - Female participants of childbearing potential must test negative for pregnancy during screening. Furthermore, female participants must agree to abstain from sexual activity or to use two different reliable methods of birth control as determined by the Investigator during the study. Examples of reliable birth control methods include true abstinence as a lifestyle choice (periodic sexual abstinence method is not acceptable); the use of oral contraceptives; a reliable barrier method of birth control (diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices) - Written informed consent from parents (and written assent from appropriately aged participants) will be obtained prior to any study procedure being performed Exclusion Criteria: - Have pulmonary hypertension related to conditions other than specified above, including but not limited to chronic thromboembolic disease, portal pulmonary hypertension, left-sided heart disease or lung disease and hypoxia - History of left-sided heart disease, including any of the following: - clinically significant [pulmonary artery occlusion pressure (PAOP) 15-18 mm Hg] aortic or mitral valve disease (ie, aortic stenosis, aortic insufficiency, mitral stenosis, moderate or greater mitral regurgitation) - pericardial constriction - restrictive or congestive cardiomyopathy - left ventricular ejection fraction <40% by multigated radionucleotide angiogram (MUGA), angiography, or echocardiography - left ventricular shortening fraction <22% by echocardiography - life-threatening cardiac arrhythmias - symptomatic coronary artery disease within 5 years of study entry - Unrepaired congenital heart disease - Have a history of angina pectoris or other condition that was treated with long- or short-acting nitrates within 12 weeks before administration of study drug - Have severe hepatic impairment, Child-Pugh Grade C - Have severe renal insufficiency, defined as receiving renal dialysis or having a measured or estimated creatinine clearance (CC) <30 millimeter per minute (mL/min) (Schwartz Formula) - Diagnosed with a retinal disorder (eg, hereditary retinal disorders, retinopathy of the preterm participant and other retinal disorders) - Have severe hypotension or uncontrolled hypertension as determined by the Investigator - Have significant parenchymal lung disease - Have bronchopulmonary dysplasia - Concurrent phosphodiesterase type 5 (PDE5) inhibitor therapy (sildenafil or vardenafil) or has received PDE5 inhibitor therapy within 12 weeks prior to the first study drug dosing - Concurrent therapy with prostacyclin or its analogues within 12 weeks of screening - Commenced or discontinued a chronic conventional PAH medication including but not restricted to: diuretics, anti-coagulants, digoxin, and oxygen therapy within 4 weeks of screening - Currently receiving treatment with doxazosin, nitrates, or cancer therapy - Current treatment with potent Cytochrome P450 3A4 (CYP3A4) inhibitors, such as antiretroviral therapy (protease inhibitor), systemic ketoconazole, or systemic itraconazole, or chronic use of potent CYP3A4 inducers, such as rifampicin - Are nursing or pregnant - Have previously completed or withdrawn from this study (LVHV), or any other study investigating tadalafil - Have received tadalafil therapy within 12 weeks prior to the first study drug dosing or are hypersensitive to tadalafil - Have allergy to the excipients, notably lactose - Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study by the Sponsor - Unable to take orally administered tablets (without chewing, crushing or breaking) or suspension - Are Investigator site personnel directly affiliated with this study or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted - Diagnosis of Down syndrome

Study Design


Intervention

Drug:
Tadalafil
Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
Placebo
Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
ERA as specific PAH treatment
All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).

Locations

Country Name City State
Austria AKH Wien
Belgium Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg Leuven
Brazil Irmandade da Santa Casa de Misericordia de Porto Alegre Porto Alegre Rio Grande Do Sul
Brazil Pronto Socorro Cardiologico de Pernambuco-PROCAPE Recife PE
Brazil Instituto Dante Pazzanese de Cardiologia Sao Paulo SP
Brazil UNIFESP - Escola Paulista de Medicina Sao Paulo SP
France CHU Hopital d'enfants de la Timone Marseille Cedex 05
France GH Necker - Enfants Malades Paris Cedex 15
France Hopital Haut Leveque - Group hospitalier Sud Pessac
France Chu de Toulouse - Hopital des Enfants Toulouse Cedex 3
Germany Universitätsklinikum Heidelberg Heidelberg Baden-Württemberg
Germany Universitätsklinikum Ulm Ulm Baden-Württemberg
Israel Schneider Medical Center Petah Tiqva
Israel Sheba Medical Center Tel Hashomer Ramat Gan
Italy Istituto Giannina Gaslini Ospedale Pediatrico I.R.C.C.S. Genova GE
Italy Ospedale V. Monaldi Napoli
Italy Ospedale Bambino Gesu Roma
Japan Asahikawa Medical College Hospital Asahikawa Hokkaido
Japan Tokyo Metropolitan Children's Medical Center Fuchu Tokyo
Japan Okinawa Prefectural Nanbu Medical Center & Children's Med Ct Haebaru-cho, Shimajiri-gun Okinawa
Japan Toho University Omori Medical Center Ohta-Ku Tokyo
Japan National Center For Child Health And Development Setagaya-ku Tokyo
Japan Gunma Children's Medical Center Shibukawa Gunma
Japan Shizuoka Prefectural Children's Hospital Shizuoka
Japan Mie University Hospital Tsu Mie
Mexico Instituto Nacional de Cardiologia Ignacio Chavez Ciudad de Mexico DF
Netherlands Universitair Medisch Centrum Groningen Groningen
Poland Uniwersyteckie Centrum Kliniczne Gdansk
Poland Uniwersytecki Szpital Dzieciecy w Krakowie-Prokocimiu Krakow
Poland Instytut Pomnik-Centrum Zdrowia Dziecka Warszawa Woj Mazowieckie
Poland Wojewódzki Szpital Specjalistyczny we Wroclawiu Wroclaw
Spain Hospital Universitari Vall d'Hebron Barcelona
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario Ramon y Cajal Madrid
Turkey Hacettepe University Faculty of Medicine Ankara
Turkey Gazi University Medical Faculty Besevler/Ankara
United States Children's Heathcare of Atlanta, Inc. at Egleston Atlanta Georgia
United States Cincinnati Childrens Hospital Medical Center Cincinnati Ohio
United States Nationwide Children's Hosp Columbus Ohio
United States Childrens Hospital of Michigan Detroit Michigan
United States Texas Childrens Hospital Houston Texas
United States Vanderbilt Univeristy School of Medicine Nashville Tennessee
United States Primary Childrens Medical Center Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Brazil,  France,  Germany,  Israel,  Italy,  Japan,  Mexico,  Netherlands,  Poland,  Spain,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters 6MWD in meters assessed in a subset of participants who are =6 to <18 years of age who are developmentally capable of performing a 6MW test. Change from baseline was derived using mixed model repeated measures (MMRM) with terms for treatment group, visit, baseline 6MWD, and treatment-by-visit interaction. Baseline, Week 24
Secondary Period 1: Time to Adjudicated Clinical Worsening (CW) Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope,initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV;only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of = 20% in the 6 minute walk distance(for those participants who are =6 years of age). Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment. Baseline through Week 24
Secondary Period 1: Percentage of Participants Who Experience CW Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope, initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication),or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV; only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of = 20% in the 6 minute walk distance(for those participants who are =6 years of age).Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment. Baseline through Week 24
Secondary Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at Steady-state Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at steady-state Week 2, Week 4, Week 16 and Week 24
Secondary Period 2: Percentage of Participants Who Experience CW Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of = 20% in the 6 minute walk distance (for those participants who are =6 years of age). Period 2 Baseline through Study Completion (Up to 24 Months)
Secondary Period 2: Time to First Occurrence of CW Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of = 20% in the 6 minute walk distance (for those participants who are =6 years of age). Period 2 Baseline through Study Completion (Up to 24 Months)
See also
  Status Clinical Trial Phase
Completed NCT04095286 - Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants Phase 1
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT02191137 - Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) Phase 4
Completed NCT01959828 - Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery Phase 3
Withdrawn NCT01202045 - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients N/A
Completed NCT00963001 - Effect of Food on the Pharmacokinetics of Oral Treprostinil Phase 1
Completed NCT00963027 - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil Phase 1
Completed NCT01121458 - Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Phase 4
Terminated NCT00825266 - Insulin Resistance in Pulmonary Arterial Hypertension Phase 4
Terminated NCT00384865 - A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension Phase 2
Active, not recruiting NCT03926572 - Acute Decompensation of Pulmonary Hypertension N/A
Completed NCT02826252 - Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20) N/A
Completed NCT02545465 - A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice N/A
Recruiting NCT04498299 - Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
Recruiting NCT02558582 - Effect of Exercise Training in Patients With Pulmonary Hypertension N/A
Active, not recruiting NCT02562235 - Riociguat in Children With Pulmonary Arterial Hypertension (PAH) Phase 3
Completed NCT02755298 - Chronic Clinical Effect of Acetazolamide Phase 2/Phase 3
Terminated NCT03043976 - Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension N/A
Completed NCT02576002 - Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension) N/A
Completed NCT01317134 - Endothelial Function in Patients With Pulmonary Arterial Hypertension N/A